Transforming Outcomes in Multiple Myeloma With Antibody-Based Regimens.

Citation metadata

Author: Graham Jackson
Date: Sept. 2021
From: Oncology(Vol. 35, Issue 9)
Publisher: Intellisphere, LLC
Document Type: Article
Length: 3,890 words
Lexile Measure: 1450L

Document controls

Main content

Article Preview :


In accordance with ACCME Guidelines, PER[R] has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Disclosures (Graham Jackson, MD, MA, MB, BS): Grant/Research Support: Bristol Myers Squibb, Takeda, Onyx; Consultant: Amgen, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Sanofi Genzyme, Takeda; Speakers' Bureau: Amgen, Bristol Myers Squibb, Johnson & Johnson, Sanofi Genzyme, Takeda.

The staff of PER[R] have no relevant financial relationships with commercial interests to disclose.


This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this activity is for accredited continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER[R] or any of the companies that provided commercial support for this activity.

This activity is supported by an educational grant from Sanofi Genzyme.


Physicians' Education Resource[R], LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource[R], LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits[TM]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity is supported by an educational grant from Sanofi Genzyme.


Mechanism of Action of Monoclonal Antibodies in Multiple Myeloma

There have been several advances in the multiple myeloma (MM) treatment landscape over the past 10 to 15 years with the introduction of proteasome inhibitors, immunomodulatory drugs, an HDAC inhibitor, the antibody-drug conjugate belantamab mafodotin, the peptide-drug conjugate melflufen, the nuclear transport inhibitor selinexor, and the particular emphasis of this article: the monoclonal antibodies. Many of these agents have been approved in relapsed/refractory myeloma and in the induction and consolidation setting. Several of these agents are now being investigated in maintenance and in smoldering MM (SMM) as well. With these advances, the median survival of patients with MM has been markedly prolonged, and the disease is evolving into a chronic illness in many patients.

There are three monoclonal antibodies that have been approved for the treatment of MM, namely daratumumab, elotuzumab, and isatuximab. A better understanding of the mechanism of action of the monoclonal antibody therapies is critical to the development of better therapeutic strategies in MM.

Monoclonal antibodies target the immune system and myeloma cells. Daratumumab and the more recently developed isatuximab both target the CD38 receptor on myeloma cells and facilitate complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and direct apoptosis of the myeloma cells. (1-5)

While daratumumab and isatuximab both target CD38 and have some overlapping mechanisms of action, there are key differences in...

Source Citation

Source Citation   

Gale Document Number: GALE|A679525845